Outlook for CRISPR-based tuberculosis assays now in their infancy.

Front Immunol · 2023 · PMC10436990 · PMID 37600797

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

Unsurprisingly, CRISPR-TB assays tended to have higher diagnostic sensitivity than Xpert, with comparable or slightly decreased specificity, in most of these studies ( Figure 1C ), although these differences did not achieve significance, likely due to the limited number of individuals in these studies.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.